Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Aug;101(2):265–271. doi: 10.1111/j.1365-2249.1995.tb08349.x

A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants.

R W Tindle 1, S Croft 1, K Herd 1, K Malcolm 1, A F Geczy 1, T Stewart 1, G J Fernando 1
PMCID: PMC1553258  PMID: 7544248

Abstract

TraT protein, known as ISCAR (= Immunostimulatory Carrier), is one of a family of integral membrane proteins (Imps) of Escherichia coli representing powerful carrier molecules which when injected into experimental animals generate substantial antibody and T proliferative responses to molecules conjugated to it. We extend these findings to show that ISCAR functions to stimulate Th1- and Th2-type responses, including specific cytotoxic T cells and tumour protection. We report here that by conjugating to ISCAR a 19mer peptide containing linear B epitopes, a T helper (Th) epitope, and a H-2b-restricted T cytotoxic (CTL) epitope of E7 protein of human papillomavirus type 16 (HPV16), and immunizing C57B1/6 (H-2b) mice, we elicited (i) specific IgG2a and IgG1 antibodies; (ii) IL-2 and IL-4 production by specifically recalled lymph node cells in vitro; (iii) cytotoxic T lymphocytes which specifically killed both E7 peptide-pulsed, and whole E7 gene-transfected tumour target cells; and (iv) in vivo protection against an E7 gene-transfected tumour cell inoculum. These findings have implications for the design of vaccines to stimulate immune responses to endogenously processed target antigens (e.g. tumour-associated antigens) without the unwanted side effects of oil-based adjuvants. In addition they support the case for a E7-targeted therapeutic vaccine for HPV-associated human cervical cancer.

Full text

PDF
265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agüero M. E., Aron L., DeLuca A. G., Timmis K. N., Cabello F. C. A plasmid-encoded outer membrane protein, TraT, enhances resistance of Escherichia coli to phagocytosis. Infect Immun. 1984 Dec;46(3):740–746. doi: 10.1128/iai.46.3.740-746.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Altmann A., Jochmus-Kudielka I., Frank R., Gausepohl H., Moebius U., Gissmann L., Meuer S. C. Definition of immunogenic determinants of the human papillomavirus type 16 nucleoprotein E7. Eur J Cancer. 1992;28(2-3):326–333. doi: 10.1016/s0959-8049(05)80047-4. [DOI] [PubMed] [Google Scholar]
  3. Chen L. P., Thomas E. K., Hu S. L., Hellström I., Hellström K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):110–114. doi: 10.1073/pnas.88.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Christensen N. D., Höpfl R., DiAngelo S. L., Cladel N. M., Patrick S. D., Welsh P. A., Budgeon L. R., Reed C. A., Kreider J. W. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol. 1994 Sep;75(Pt 9):2271–2276. doi: 10.1099/0022-1317-75-9-2271. [DOI] [PubMed] [Google Scholar]
  5. Cooper P. D., Turner R., McGovern J. Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice. Immunol Lett. 1991 Feb;27(2):131–134. doi: 10.1016/0165-2478(91)90140-6. [DOI] [PubMed] [Google Scholar]
  6. Croft S., Walsh J., Lloyd W., Russell-Jones G. J. TraT: a powerful carrier molecule for the stimulation of immune responses to protein and peptide antigens. J Immunol. 1991 Feb 1;146(3):793–798. [PubMed] [Google Scholar]
  7. Crook T., Storey A., Almond N., Osborn K., Crawford L. Human papillomavirus type 16 cooperates with activated ras and fos oncogenes in the hormone-dependent transformation of primary mouse cells. Proc Natl Acad Sci U S A. 1988 Dec;85(23):8820–8824. doi: 10.1073/pnas.85.23.8820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de Jongh B. M., Drijfhout J. W., ter Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993 Sep;23(9):2242–2249. doi: 10.1002/eji.1830230929. [DOI] [PubMed] [Google Scholar]
  9. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  10. Hawley-Nelson P., Vousden K. H., Hubbert N. L., Lowy D. R., Schiller J. T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989 Dec 1;8(12):3905–3910. doi: 10.1002/j.1460-2075.1989.tb08570.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hopp T. P. Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier. Mol Immunol. 1984 Jan;21(1):13–16. doi: 10.1016/0161-5890(84)90084-1. [DOI] [PubMed] [Google Scholar]
  12. Hu-Li J., Ohara J., Watson C., Tsang W., Paul W. E. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol. 1989 Feb 1;142(3):800–807. [PubMed] [Google Scholar]
  13. Jochmus-Kudielka I., Schneider A., Braun R., Kimmig R., Koldovsky U., Schneweis K. E., Seedorf K., Gissmann L. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J Natl Cancer Inst. 1989 Nov 15;81(22):1698–1704. doi: 10.1093/jnci/81.22.1698. [DOI] [PubMed] [Google Scholar]
  14. Kadish A. S., Romney S. L., Ledwidge R., Tindle R., Fernando G. J., Zee S. Y., Van Ranst M. A., Burk R. D. Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific. J Gen Virol. 1994 Sep;75(Pt 9):2277–2284. doi: 10.1099/0022-1317-75-9-2277. [DOI] [PubMed] [Google Scholar]
  15. Kast W. M., Brandt R. M., Sidney J., Drijfhout J. W., Kubo R. T., Grey H. M., Melief C. J., Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994 Apr 15;152(8):3904–3912. [PubMed] [Google Scholar]
  16. Kast W. M., Brandt R. M., Sidney J., Drijfhout J. W., Kubo R. T., Grey H. M., Melief C. J., Sette A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol. 1994 Apr 15;152(8):3904–3912. [PubMed] [Google Scholar]
  17. Kast W. M., Offringa R., Peters P. J., Voordouw A. C., Meloen R. H., van der Eb A. J., Melief C. J. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell. 1989 Nov 17;59(4):603–614. doi: 10.1016/0092-8674(89)90006-8. [DOI] [PubMed] [Google Scholar]
  18. Labeit D., Back W., von Weizsäcker F., Hermann P., Melchert F., Leonard K., Labeit S. Increased detection of HPV 16 virus in invasive, but not in early cervical cancers. J Med Virol. 1992 Feb;36(2):131–135. doi: 10.1002/jmv.1890360210. [DOI] [PubMed] [Google Scholar]
  19. Lambert P. F., Pan H., Pitot H. C., Liem A., Jackson M., Griep A. E. Epidermal cancer associated with expression of human papillomavirus type 16 E6 and E7 oncogenes in the skin of transgenic mice. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5583–5587. doi: 10.1073/pnas.90.12.5583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lowell G. H., Ballou W. R., Smith L. F., Wirtz R. A., Zollinger W. D., Hockmeyer W. T. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science. 1988 May 6;240(4853):800–802. doi: 10.1126/science.2452484. [DOI] [PubMed] [Google Scholar]
  21. Melancon J., Murgita R. A., Devoe I. W. Activation of murine B lymphocytes by Neisseria meningitidis and isolated meningococcal surface antigens. Infect Immun. 1983 Nov;42(2):471–479. doi: 10.1128/iai.42.2.471-479.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  23. Müller M., Viscidi R. P., Sun Y., Guerrero E., Hill P. M., Shah F., Bosch F. X., Muñoz N., Gissmann L., Shah K. V. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16-associated invasive cervical cancer. Virology. 1992 Apr;187(2):508–514. doi: 10.1016/0042-6822(92)90453-v. [DOI] [PubMed] [Google Scholar]
  24. Pfister H. Biology and biochemistry of papillomaviruses. Rev Physiol Biochem Pharmacol. 1984;99:111–181. doi: 10.1007/BFb0027716. [DOI] [PubMed] [Google Scholar]
  25. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol. 1994;12:227–257. doi: 10.1146/annurev.iy.12.040194.001303. [DOI] [PubMed] [Google Scholar]
  26. Romagnani S., Maggi E. Th1 versus Th2 responses in AIDS. Curr Opin Immunol. 1994 Aug;6(4):616–622. doi: 10.1016/0952-7915(94)90150-3. [DOI] [PubMed] [Google Scholar]
  27. Russell-Jones G. J., Sullivan J. S., Geczy A. F. Peptide sequences with strong stimulatory activity for lymphoid cells: implications for vaccine development. Vaccine. 1993 Oct;11(13):1310–1315. doi: 10.1016/0264-410x(93)90100-c. [DOI] [PubMed] [Google Scholar]
  28. Seppälä I. J., Mäkelä O. Adjuvant effect of bacterial LPS and/or alum precipitation in responses to polysaccharide and protein antigens. Immunology. 1984 Dec;53(4):827–836. [PMC free article] [PubMed] [Google Scholar]
  29. Shu S. Y., Rosenberg S. A. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res. 1985 Apr;45(4):1657–1662. [PubMed] [Google Scholar]
  30. Smotkin D., Wettstein F. O. The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein. J Virol. 1987 May;61(5):1686–1689. doi: 10.1128/jvi.61.5.1686-1689.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Swain S. L. IL4 dictates T-cell differentiation. Res Immunol. 1993 Oct;144(8):616–620. doi: 10.1016/s0923-2494(05)80013-6. [DOI] [PubMed] [Google Scholar]
  32. Tindle R. W., Fernando G. J., Sterling J. C., Frazer I. H. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5887–5891. doi: 10.1073/pnas.88.13.5887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Tindle R. W., Smith J. A., Geysen H. M., Selvey L. A., Frazer I. H. Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. J Gen Virol. 1990 Jun;71(Pt 6):1347–1354. doi: 10.1099/0022-1317-71-6-1347. [DOI] [PubMed] [Google Scholar]
  34. Walden P. R., Eisen H. N. Cognate peptides induce self-destruction of CD8+ cytolytic T lymphocytes. Proc Natl Acad Sci U S A. 1990 Nov;87(22):9015–9019. doi: 10.1073/pnas.87.22.9015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. de Villiers E. M., Hirsch-Behnam A., von Knebel-Doeberitz C., Neumann C., zur Hausen H. Two newly identified human papillomavirus types (HPV 40 and 57) isolated from mucosal lesions. Virology. 1989 Jul;171(1):248–253. doi: 10.1016/0042-6822(89)90532-1. [DOI] [PubMed] [Google Scholar]
  36. von Knebel Doeberitz M., Rittmüller C., Aengeneyndt F., Jansen-Dürr P., Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol. 1994 May;68(5):2811–2821. doi: 10.1128/jvi.68.5.2811-2821.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 1989 Sep 1;49(17):4677–4681. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES